SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 3:00 p.m. ET. A live webcast of the event will be available in the Investors se ...

Group 1 - Maze Therapeutics' Senior Vice President of Finance, Amy Bachrodt, sold 5,000 shares for approximately $227,612 on January 22, 2026, following a strong performance of the company's stock [1][2] - The company has seen a remarkable 1-year price change of 172.38%, with a significant increase of 158% in 2025 after its IPO on January 31, 2025 [4][6] - Following the transaction, Bachrodt's direct ownership decreased to 12,965 shares, representing 0.0269% of the company's outstanding shares [8] Group 2 - Maze Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for renal, cardiovascular, and metabolic diseases, including obesity [5] - The company is advancing to later clinical stages for its medicines targeting kidney and metabolic diseases, which are expected to generate significant revenue upon trial completion [9] - The stock has shown consistent gains for nine months post-IPO, but investors should be cautious of potential short-term drawdowns due to the sustained high buying power [6][7]

Core Insights - Maze Therapeutics is addressing inefficiencies in drug development by leveraging Genome-Wide Association Studies to identify disease-associated loci, which the industry has struggled to translate into effective treatments [1] Group 1: Company Overview - Maze Therapeutics focuses on converting genetic signals into therapeutic solutions, filling a critical gap in the pharmaceutical industry [1] Group 2: Market Themes - The investment portfolio is centered around five key themes: Semiconductor Supply Chain, Grid/Power/Energy Transition, Critical Materials, Biotechnology, and Artificial Intelligence/Cloud Computing [1]

Maze Therapeutics (NasdaqGM:MAZE) FY Conference January 12, 2026 11:15 AM ET Company ParticipantsJason Coloma - CEOConference Call ParticipantsNone - AnalystAnupam Rama - Senior Biotech AnalystAnupam RamaWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my squad, Joyce Zhou, Priyanka Grover, and Rathi Pinhey. Our next presenting company is Maze Therapeutics, and presenting on behalf of the comp ...

How does this transaction fit with available capacity and historical activity? The scale of the sale is dictated by the exercise of a single large option grant, with remaining share capacity now limited, and aligns with administrative vesting rather than a pattern of multiple open-market sales.What portion of Dandekar's remaining exposure is now in options versus common stock? Based on disclosures, the majority of Dandekar's residual exposure is now derivative-based.How does the derivative context affect in ...

Core Viewpoint - Maze Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule precision medicines for kidney and metabolic diseases, with a presentation scheduled at the J.P. Morgan Healthcare Conference [1]. Company Overview - Maze Therapeutics utilizes human genetics to create novel small molecule precision medicines targeting kidney and metabolic diseases, including obesity [3]. - The company operates its Compass™ platform to identify genetically validated targets, integrating variant discovery and functionalization to advance small molecule programs with first- or best-in-class potential [3]. - The pipeline includes MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 for APOL1-mediated kidney disease, and MZE782, a SLC6A19 inhibitor advancing to Phase 2 for phenylketonuria and chronic kidney disease [3]. - Maze Therapeutics is headquartered in South San Francisco [3].

Summary of Maze Therapeutics FY Conference Call (December 03, 2025) Company Overview - **Company**: Maze Therapeutics (NasdaqGM: MAZE) - **Focus**: Development of therapies for genetically defined diseases, particularly APOL1-mediated kidney disease Key Accomplishments in 2025 - **Public Offering**: Maze Therapeutics went public early in 2025, enabling significant transformation and capital acquisition for further development [4][5] - **Clinical Trials**: Initiated study for MZE829 targeting APOL1 kidney disease, with data expected by the end of Q1 2026 [4][5] - **Second Program**: Additional data on MZE782 was well received, leading to a small PIPE financing [4][5] APOL1 Kidney Disease Insights - **Patient Demographics**: Affects approximately 6 million individuals in the U.S., with about 1 million having kidney disease; around 250,000 could benefit from therapy [7][8] - **Disease Characteristics**: Patients are generally younger and progress to dialysis about 10 years earlier than non-APOL1 patients [7][8] - **Current Treatment Gap**: No approved therapies exist for APOL1 kidney disease, and current standard care is ineffective [8][10] Mechanism of Action for MZE829 - **Targeting APOL1**: MZE829 aims to block the toxic gain of function caused by APOL1 variants G1 and G2, which lead to kidney toxicity [11][12] - **Differentiation from Competitors**: MZE829 has a dual mechanism of action, blocking pore formation and disrupting assembly, which differentiates it from Vertex's inaxaplin [12][13] Clinical Trial Design - **Horizon Study**: Enrolling patients with G1 or G2 genotypes, aiming for a 30% reduction in proteinuria as measured by UACR [16][18] - **Inclusion Criteria**: Includes both diabetic and non-diabetic patients, with a longer lead-in time of eight weeks to ensure accurate measurement of treatment effects [20][32] Regulatory Considerations - **UACR as Endpoint**: UACR is a sensitive measure for proteinuria, and a 30% reduction is considered clinically significant, correlating with improved eGFR and reduced risk of end-stage kidney disease [33][34] Future Plans - **Next Steps**: If successful data is obtained, planning for a phase 2b/3 study will commence, similar to Vertex's Amplitude study [36][41] - **2026 Objectives**: Key events include the release of APOL1 kidney disease data and the initiation of two phase 2 studies based on promising data from MZE782 [46] Market Landscape - **Competitive Environment**: The landscape for APOL1-mediated kidney disease is evolving, with interest from large pharmaceutical companies. Maze Therapeutics aims to establish itself as a leader in this space [40][41] - **Potential for Multiple Players**: The unmet need in this area suggests opportunities for various companies to develop effective therapies [42][44] Conclusion - **Significant Year Ahead**: 2026 is poised to be a pivotal year for Maze Therapeutics, with critical data releases and potential advancements in their clinical programs [46]

Company Overview - Maze Therapeutics aims to leverage human genetics to improve patient outcomes, particularly focusing on chronic kidney disease, which affects over 800 million people globally and is the 9th leading cause of death [2] Industry Context - Chronic kidney disease is characterized by a lack of innovation and precision medicine approaches, creating a significant opportunity for companies like Maze Therapeutics to fill this gap [2] Product Pipeline - The lead product, MZE829, targets APOL1-mediated kidney disease, with an estimated 1 million individuals in the U.S. who could benefit from this treatment. The company is currently enrolling patients for Phase II trials, expecting to present clinical proof-of-concept data by Q1 2026 [3] - The second program, MZE782, focuses on SLC6A19 and is being developed for phenylketonuria (PKU). The company has already demonstrated clinical proof of mechanism for this approach in chronic kidney disease [4]

Summary of Maze Therapeutics Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM:MAZE) - **Focus**: Development of small molecules targeting chronic kidney disease and metabolic diseases using a genetics approach [1] Industry Context - **Chronic Kidney Disease**: Affects over 800 million individuals globally and is the ninth leading cause of death [1] - **APOL1-mediated Kidney Disease**: At least 1 million individuals in the U.S. could benefit from targeted therapies [2] Key Programs and Developments MZE829 for APOL1-mediated Kidney Disease - **Phase Two Enrollment**: Ongoing with intent to present clinical proof of concept data in Q1 2026 [2][3] - **Target Population**: Focus on broad AMKD patients, including those with and without diabetes [2][7] - **Mechanism of Action**: Dual mechanism targeting the APOL1 gene, differentiating from other compounds [9][10] - **Clinical Proof of Concept Goal**: Aiming for a 30% reduction in UACR relative to baseline [12][26] MZE782 for Phenylketonuria (PKU) - **Phase Two Initiation**: Planned for 2026, targeting a broad spectrum of PKU patients [13][15] - **Clinical Proof of Concept**: Recent data showed a 40-fold increase in urinary Phe excretion, indicating strong pharmacodynamic response [18] SLC6A19 in Chronic Kidney Disease - **Potential Impact**: Identified genetic relationships that could lead to new treatment options, potentially becoming a new standard in kidney disease management [19][20] - **Comparative Efficacy**: Demonstrated superior efficacy in reducing proteinuria compared to SGLT2 inhibitors [21][22] Financial and Strategic Position - **Capitalization**: Successfully completed financing in September, positioning the company to deliver on upcoming data catalysts [27] - **Vision**: Aim to become a leading precision medicine company in kidney and metabolic diseases, with ongoing development of additional small molecules [28][29] Additional Insights - **Demographics of APOL1 Kidney Disease**: Disproportionately affects younger individuals, particularly in the Black community, with faster progression to end-stage renal disease [5][6] - **Regulatory Landscape**: Evolving understanding of kidney disease treatment pathways, with plans for pivotal studies based on upcoming data [5][26] - **Collaboration Potential**: Opportunities for partnerships to advance additional programs, as demonstrated with the Pompe program [29]

Summary of Maze Therapeutics Conference Call Company Overview - **Company**: Maze Therapeutics (NasdaqGM:MAZE) - **Focus**: Development of small molecule precision medicines, primarily targeting kidney diseases, particularly APOL1-mediated kidney disease [4][11] Key Highlights from the American Society of Nephrology (ASN) Conference - **Abstracts**: Maze Therapeutics had seven abstracts accepted at ASN, showcasing significant research contributions [4] - **Genotyping Study**: - Previous literature indicated that approximately 13% of the general population has pathogenic variants causing APOL1 kidney disease - Maze's study found about 18% prevalence in enriched kidney disease patients, indicating a higher incidence due to the specific population studied [5][6] - Approximately 1 million individuals in the U.S. have these variants, with at least 250,000 potentially benefiting from therapy [5] - Breakdown: 40% of affected individuals have diabetes, while 60% do not [6] - **Disease Progression**: - The progression of APOL1-mediated kidney disease occurs at similar rates in patients with and without diabetes [6][7] - A protective variant, N264K, was identified, showing protective effects regardless of diabetes status [7][19] Mechanistic Insights - **Pathogenic Mechanism**: APOL1 variants lead to nephrotoxicity through aberrant pore channel function in podocytes [9][10] - **Therapeutic Approach**: Maze's dual mechanism APOL1 inhibitor aims to block the pore and disrupt its assembly, showing significant potency advantages in preclinical models [11][12] Clinical Development Plans - **Maze 829 Program**: - Aiming for clinical proof of concept (POC) in broad APOL1-mediated kidney disease by Q1 2026, targeting a minimum 30% reduction in proteinuria [12][13] - The 30% threshold is based on historical data correlating with clinical significance and regulatory guidelines [21][23] - **Patient Cohorts**: Expecting data from both diabetes and non-diabetes cohorts, with a focus on demonstrating POC in a broader patient population [14][15] Market Potential - **Patient Population**: The broader AMKD landscape includes approximately 250,000 patients, significantly larger than the FSGS population [31][32] - **Comparative Advantage**: Maze aims to differentiate its therapy from existing treatments like inaxaplin by demonstrating superior efficacy and safety profiles [34][44] Additional Insights on SLC6A19 (782) Program - **PKU Treatment**: The therapy targets severe classical PKU, aiming to reduce plasma phenylalanine levels significantly, with a goal of improving patient outcomes [39][40] - **CKD Insights**: The program has shown promise in improving kidney health, with genetic associations and in vivo proof of concept supporting its efficacy [41][42] Conclusion - Maze Therapeutics is positioned to potentially lead in the treatment of APOL1-mediated kidney disease with its innovative therapeutic approaches and significant market opportunity, while also exploring promising avenues in PKU and CKD treatments [44][46]